<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> is one of the leading causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> worldwide, with disease progression and metastatic spread being closely associated with <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether an antiangiogenic gene transfer approach using the Sleeping Beauty (SB) transposon system could be used to inhibit growth of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> metastatic to the liver </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Liver CT26 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice were hydrodynamically injected with different doses of a plasmid containing a transposon encoding an angiostatin-endostatin fusion gene (<z:chebi fb="0" ids="35664">Statin</z:chebi> AE) along with varying amounts of SB transposase-encoding plasmid </plain></SENT>
<SENT sid="3" pm="."><plain>Animals that were injected with a low dose (10 μg) of <z:chebi fb="0" ids="35664">Statin</z:chebi> AE transposon plasmid showed a significant decrease in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation only when co-injected with SB transposase-encoding plasmid, while for animals injected with a higher dose (25 μg) of <z:chebi fb="0" ids="35664">Statin</z:chebi> AE transposon, co-injection of SB transposase-encoding plasmid did not significantly affect <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load </plain></SENT>
<SENT sid="4" pm="."><plain>For animals injected with 10 μg <z:chebi fb="0" ids="35664">Statin</z:chebi> AE transposon plasmid, the number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> nodules was inversely proportional to the amount of co-injected SB plasmid </plain></SENT>
<SENT sid="5" pm="."><plain>Suppression of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> was further evident in histological analyses, in which untreated animals showed higher levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell proliferation and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vascularization than animals treated with low dose transposon plasmid </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: These results demonstrate that hepatic colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> can be reduced using antiangiogenic transposons, and provide evidence for the importance of the transposition process in mediating suppression of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>